Search Results 31-40 of 6318 for younkin

  1. clinicaltrials gov.

  2. Untitled

    Page 1.

  3. Speakers - Mayo Foundation Rising Stars Symposium - Mayo Clinic Research

    Fiesel received a postdoctoral fellowship from the American Parkinson Disease Association, a Younkin Scholar Award and a Gerstner Family Career Development ...

  4. 5th Annual Neuro and Intensive Care Review Workshops and Controversies.

  5. A Study to Assess the Safety, Tolerability, and Effectiveness of KPT-9274 to Treat Patients who have Advanced Solid Malignancies or Non-Hodgkin's Lymphoma - Mayo Clinic

    Inclusion Criteria. Advanced solid malignancies or Non-Hodgkins lymphoma for which all standard therapeutic options considered useful have been exhausted ...

  6. John L. Graner, M.D. - Mayo Clinic Faculty Profiles

    My research interests are focused on the history of medicine. Mayo Clinic, William Osler, Harvey Cushing, late 19th and early 20th century medicine are of ...

  7. Publications - Phillip A. Low, M.D. - Mayo Clinic

    ... Younkin SG, Wszolek ZK, Low PA, Singer W, Bu G, Dickson DW, Ross OA ... Younkin SG, Boeve BF, Cheshire WP Jr, Low PA, Sandroni P, Coon EA, Singer W ...

  8. A Registry Called Every Child for Collecting Data and Biology Specimens on Younger Patients with Cancer - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. Publications - Erik J. Tryggestad, Ph.D. - Mayo Clinic

    Shen J, Tryggestad E, Younkin JE, Keole SR, Furutani KM, Kang Y, Herman MG, Bues M. Technical Note: Using experimentally determined proton spot scanning ...

  10. Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...